Trials of tivantinib, a c-Met inhibitor, and foretinib, a c-Met/vascular endothelial growth factor receptor 2 inhibitor, in unselected gastric cancer patients have shown no objective responses [13, 14]. The gene discussed is KDR; the disease is gastric cancer.